Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain pept...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology 2014-12, Vol.3 (12), p.e941737-e941737
Hauptverfasser: van Luijn, Marvin M, van den Ancker, Willemijn, van Ham, S Marieke, van de Loosdrecht, Arjan A
Format: Artikel
Sprache:eng
Schlagworte:
Author's View
CD4
HLA
immune escape
leukemia-associated phenotype
minimal residual disease
T cells
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/21624011.2014.941737